Clinical evaluation of anticancer alkylating agent, carboquone (NSG-134679).
D000284:Administration, Oral; D001389:Azirines / Q000627:therapeutic use*; D002225:Carbazilquinone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*
D001389:Azirines; D002225:Carbazilquinone